Glenmark Pharmaceuticals to Respond to Patent Row With Merck & Co., Inc. Next Month

Published: Apr 15, 2013

The Delhi High Court on Friday sought response of Glenmark Pharmaceuticals on US drug major Merck Sharp and Dohme's appeal against the single judge bench order refusing to restrain the Indian firm from manufacturing and selling anti-diabetes drugs Zita and Zita-Met. A bench of Justices S Ravindra Bhat and S K Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging the single judge order. The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation of intellectual property rights (IPR) used in its drugs Januvia and Janumet. On April 5, a single judge bench of Justice Rajiv Sahai Endlaw, in an interim order, had refused to restrain the Indian company from manufacturing and selling its anti- diabetes medicines.

Back to news